X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

ARWR

Closed

Arrowhead Pharmaceuticals Inc

16.09
+0.29 (+1.84%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 15.8
Day's Range: 15.33 - 16.54
Send
When Written:
 
25.4
Arrowhead Pharmaceuticals Inc is a biopharmaceutical company that specializes in developing RNA interference (RNAi) therapies for the treatment of various diseases. The company's RNAi technology is designed to silence disease-causing genes, offering a potential new approach to treating a wide range of diseases.

Arrowhead Pharmaceuticals Inc was founded in 2007 and is headquartered in Pasadena, California. The company has a diverse pipeline of RNAi therapeutics in various stages of development, with a focus on liver diseases, oncology, and genetic disorders.

The company's lead product candidate is ARO-AAT, which is being developed for the treatment of alpha-1 antitrypsin deficiency, a genetic disorder that can cause lung and liver disease. Arrowhead Pharmaceuticals Inc also has several other product candidates in development, including ARO-HIF2 for the treatment of renal cell carcinoma, ARO-ENaC for the treatment of cystic fibrosis, and ARO-ANG3 for the treatment of dyslipidemia.

Arrowhead Pharmaceuticals Inc has partnerships with several pharmaceutical companies, including Amgen, Janssen Pharmaceuticals, and Takeda Pharmaceutical Company Limited. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol ARWR.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X